Market cap
$104 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
7.2
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | -- | -- | 38.09 | 9.36 | 3.51 |
| Net Profit | 0.35 | 8.35 | 16.89 | 2.99 | 0.66 |
| EPS | -- | -- | -- | -- | -- |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Oct-25 | Oct-24 |
| EBIT-Margin
| -4,728.57 | -2,431.92 | -- | -- | -- |
| Net Margin
| -- | -0.55 | -- | -- | -- |
| Return on equity
| -51.85 | -51.26 | -67.38 | -62.16 | -56.63 |
| Return on Capital
| -51.33 | -50.80 | -- | -61.40 | -56.12 |
| Return on Assets
| -48.80 | -48.76 | -57.19 | -58.01 | -53.29 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.01 | 0.01 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Oct-25
|
Oct-24
|
Oct-23
|
Oct-22
|
|---|---|---|---|---|---|
|
Anixa Biosciences (ANIX)
|
--
|
-61.40
|
-56.12
|
-36.49
|
-41.85
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-67.38
Lower than Peers by 26.99
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Oct-25
|
Oct-24
|
Oct-23
|
Oct-22
|
|---|---|---|---|---|---|
|
Anixa Biosciences (ANIX)
|
-67.38
|
-62.16
|
-56.63
|
-36.76
|
-42.17
|
|
Peer Median
|
-40.40
|
--
|
--
|
--
|
--
|
ROA
-57.19
Lower than Peers by 26.21
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Oct-25
|
Oct-24
|
Oct-23
|
Oct-22
|
|---|---|---|---|---|---|
|
Anixa Biosciences (ANIX)
|
-57.19
|
-58.01
|
-53.29
|
-35.08
|
-40.78
|
|
Peer Median
|
-30.98
|
--
|
--
|
--
|
--
|
EBIT Margin
--
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Oct-25
|
Oct-24
|
Oct-23
|
Oct-22
|
|---|---|---|---|---|---|
|
Anixa Biosciences (ANIX)
|
--
|
--
|
--
|
-4,728.57
|
-0.56
|
|
Peer Median
|
-83.62
|
--
|
--
|
--
|
--
|
Net Margin
--
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Oct-25
|
Oct-24
|
Oct-23
|
Oct-22
|
|---|---|---|---|---|---|
|
Anixa Biosciences (ANIX)
|
--
|
--
|
--
|
-4,671.90
|
-0.55
|
|
Peer Median
|
-92.67
|
--
|
--
|
--
|
--
|
Revenue Growth
--
--
Year on year growth in net sales
|
Company Name
|
TTM
|
Oct-25
|
Oct-24
|
Oct-23
|
Oct-22
|
|---|---|---|---|---|---|
|
Anixa Biosciences (ANIX)
|
--
|
--
|
-1.00
|
-1.00
|
4,821.27
|
|
Peer Median
|
53.95
|
--
|
--
|
--
|
--
|
EBIT Growth
38.09
Higher than Peers by 38.89
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Oct-25
|
Oct-24
|
Oct-23
|
Oct-22
|
|---|---|---|---|---|---|
|
Anixa Biosciences (ANIX)
|
38.09
|
13.15
|
-27.88
|
27.89
|
-4.79
|
|
Peer Median
|
-0.80
|
--
|
--
|
--
|
--
|
Net Profit Growth
16.89
Higher than Peers by 24.19
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Oct-25
|
Oct-24
|
Oct-23
|
Oct-22
|
|---|---|---|---|---|---|
|
Anixa Biosciences (ANIX)
|
16.89
|
12.96
|
-27.96
|
27.83
|
-5.01
|
|
Peer Median
|
-7.30
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Oct-25
|
Oct-24
|
Oct-23
|
Oct-22
|
|---|---|---|---|---|---|
|
Anixa Biosciences (ANIX)
|
--
|
0.01
|
0.01
|
0.01
|
0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.00
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Oct-25
|
Oct-24
|
Oct-23
|
Oct-22
|
|---|---|---|---|---|---|
|
Anixa Biosciences (ANIX)
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
9.79
Higher than Peers by 3.98
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Oct-25
|
Oct-24
|
Oct-23
|
Oct-22
|
|---|---|---|---|---|---|
|
Anixa Biosciences (ANIX)
|
9.79
|
8.08
|
8.54
|
12.50
|
14.83
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
9.79
Higher than Peers by 4.09
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Oct-25
|
Oct-24
|
Oct-23
|
Oct-22
|
|---|---|---|---|---|---|
|
Anixa Biosciences (ANIX)
|
9.79
|
--
|
--
|
--
|
14.85
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Oct-25
|
Oct-24
|
Oct-23
|
Oct-22
|
|---|---|---|---|---|---|
|
Anixa Biosciences (ANIX)
|
--
|
--
|
--
|
--
|
-132.41
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
--
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Oct-25
|
Oct-24
|
Oct-23
|
Oct-22
|
|---|---|---|---|---|---|
|
Anixa Biosciences (ANIX)
|
--
|
--
|
--
|
128.57
|
0.00
|
|
Peer Median
|
19.14
|
--
|
--
|
--
|
--
|
Asset Turnover
--
--
Sales / Average Total Assets
|
Company Name
|
TTM
|
Oct-25
|
Oct-24
|
Oct-23
|
Oct-22
|
|---|---|---|---|---|---|
|
Anixa Biosciences (ANIX)
|
--
|
--
|
--
|
0.01
|
74.07
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Oct-25
|
Oct-24
|
Oct-23
|
Oct-22
|
|---|---|---|---|---|---|
|
Anixa Biosciences (ANIX)
|
--
|
--
|
--
|
274.81
|
0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Oct-25
|
Oct-24
|
Oct-23
|
Oct-22
|
|---|---|---|---|---|---|
|
Anixa Biosciences (ANIX)
|
--
|
--
|
--
|
-104.36
|
-400.04
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Oct-25
|
Oct-24
|
Oct-23
|
Oct-22
|
|---|---|---|---|---|---|
|
Anixa Biosciences (ANIX)
|
--
|
3,500.31
|
3,608.08
|
534.26
|
1,743.63
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Oct-25
|
Oct-24
|
Oct-23
|
Oct-22
|
|---|---|---|---|---|---|
|
Anixa Biosciences (ANIX)
|
--
|
--
|
--
|
-363.81
|
-2,143.66
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Book Value
7.15
Higher than Peers by 1.97
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Oct-25
|
Oct-24
|
Oct-23
|
Oct-22
|
|---|---|---|---|---|---|
|
Anixa Biosciences (ANIX)
|
7.15
|
--
|
--
|
--
|
--
|
|
Peer Median
|
5.18
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Oct-25
|
Oct-24
|
Oct-23
|
Oct-22
|
|---|---|---|---|---|---|
|
Anixa Biosciences (ANIX)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-8.76
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Oct-25
|
Oct-24
|
Oct-23
|
Oct-22
|
|---|---|---|---|---|---|
|
Anixa Biosciences (ANIX)
|
-8.76
|
1.36
|
1.56
|
2.39
|
2.15
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
104
Lower than Peers by 42
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Oct-25
|
Oct-24
|
Oct-23
|
Oct-22
|
|---|---|---|---|---|---|
|
Anixa Biosciences (ANIX)
|
104
|
--
|
--
|
--
|
--
|
|
Peer Median
|
146
|
--
|
--
|
--
|
--
|